// App-Quantinova.ai

589 : Xevinapant plus nivolumab in patients with advanced solid tumors who progressed on prior anti–PD-1/PD-L1 treatment: results of a dose-optimization, exploratory phase 1b/2 trial

Researchers

Presenter

  • Emiliano Calvo Aller

Principal Investigators

  • Glenn Hanna

  • Maria Vieito Villar

  • Caroline Even

  • Victor Moreno

  • Chul Kim

  • Shuchi Gulati

  • Daniel Morgensztern

  • Ana Acuna-Villaorduna

  • Philippe Cassier

  • Dennie Jones

  • Florilene Bouisset

  • Daniela Sahlender

  • Elisabeth Rouits

  • Dany Spaggiari

  • Lars Damstrup

  • Carlos-Alberto Gomez-Roca

Medical Centers

  • Washington University School of Medicine, St. Louis, MO

  • Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC

  • University of Florida, Jacksonville, Florida, United States

  • Debiopharm International SA, Lausanne, Switzerland

  • Montefiore Medical Center PRIME, Bronx, NY, United States

  • START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain

  • Institut Gustave Roussy, Villejuif, Ile-de-France, France

  • Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain

  • University of Cincinnati, Cincinnati, OH, United States

  • Centre Leon Berard, Lyon, Rhone-Alpes, France

  • Hospital Universitari Vall d'Hebron, Spain

  • Institut Claudius Regaud, Toulouse, Haute Garonne, France

  • Dana-Farber Cancer Institute, Boston, MA, United States

Locations

  • United States

  • Switzerland

  • France

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Squamous cell carcinoma of the head and neck

  • Mismatch repair deficiency

  • Gastric Cancer

  • Squamous cell carcinoma

  • Small cell lung cancer

  • Solid malignancies

  • Gynaecological cancer

  • Lung Cancer

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • Microsatellite instability-high

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • NCT04122625

Sponsors

  • The Healthcare Business of Merck KGaA

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved